Oncolytics Biotech Inc. Announces AGM Voting Results
Oncolytics Biotech Inc. (NASDAQ: ONCY) has recently shared the outcomes of its Annual General Meeting (AGM) held on August 8, 2025. This meeting is pivotal for the company as it gathers shareholder input and elects board members. A total of 37.42% of the company’s common shares were represented at the meeting, reflecting the engagement of stakeholders in the corporation's affairs.
Election of Directors
In a unanimous decision, shareholders voted to elect eight nominees to serve as directors of Oncolytics. These directors will hold their positions until the next AGM or until their successors are appointed. The voting indicated impressive support for individual nominees, highlighting shareholders' confidence in the leadership team.
Individual Voting Results
The election results showcased the following votes for each director:
- Patricia Andrews - 10,498,328 votes (88.83%) in favor, 1,320,714 withheld (11.17%).
- Deborah M. Brown - 10,115,110 votes (85.58%) in favor, 1,703,932 withheld (14.42%).
- Jared Kelly - 10,830,605 votes (91.64%) in favor, 988,437 withheld (8.36%).
- Angela Holtham - 10,175,887 votes (86.10%) in favor, 1,643,155 withheld (13.90%).
- James T. Parsons - 10,172,958 votes (86.07%) in favor, 1,646,084 withheld (13.93%).
- Wayne Pisano - 10,148,894 votes (85.87%) in favor, 1,670,148 withheld (14.13%).
- Jonathan Rigby - 9,508,770 votes (80.45%) in favor, 2,310,272 withheld (19.55%).
- Bernd R. Seizinger - 10,269,441 votes (86.89%) in favor, 1,549,601 withheld (13.11%).
Shareholder Approvals for Resolutions
In addition to electing the directors, Oncolytics’ shareholders approved other important resolutions during the AGM. These included fixing the number of directors at eight and appointing auditors for the upcoming year. Such endorsements signify trust in the governance and oversight of the company.
About Oncolytics Biotech Inc.
Oncolytics is an innovative clinical-stage biotechnology firm dedicated to developing its leading product, pelareorep, an intravenous immunotherapy. This therapy has shown encouraging potential in various cancer trials, particularly in pancreatic and breast cancers. Pelareorep works by activating both innate and adaptive immune responses, making previously 'cold' tumors respond to treatment effectively.
Strategic Developments and Partnerships
The company is not resting on its laurels. They are actively enhancing pelareorep's profile through collaborations with chemotherapy and checkpoint inhibitors, especially in aggressive cancer types such as metastatic pancreatic cancer. These strategic partnerships aim to expedite research and significantly boost commercial outcomes in the oncology market.
Future Updates
For further information related to the AGM and additional updates, investors can keep abreast through the company’s communications. As Oncolytics continues to leverage innovation in immunotherapy, they invite stakeholders to follow their journey into new frontiers of cancer treatment.
Frequently Asked Questions
What was the main outcome of the Oncolytics Biotech AGM?
The main outcome included the election of eight directors and the approval of other essential resolutions by shareholders.
Who were the elected directors at the AGM?
The elected directors included Patricia Andrews, Deborah M. Brown, Jared Kelly, Angela Holtham, James T. Parsons, Wayne Pisano, Jonathan Rigby, and Bernd R. Seizinger.
What percentage of shares were represented at the AGM?
A total of 37.42% of the issued shares were represented at the meeting.
What is pelareorep?
Pelareorep is an intravenously delivered immunotherapeutic agent developed by Oncolytics that has shown potential in treating various cancer types.
How is Oncolytics pursuing growth in the market?
Oncolytics is focusing on strategic partnerships to enhance the development and commercial potential of pelareorep, particularly in aggressive cancers.
